Betthauser Kevin, Pope Hannah, Gowan Mollie, Human Theresa
Department of Pharmacy, Barnes-Jewish Hospital, 216 S. Kingshighway Boulevard, Mailstop 90-52-411, St. Louis, MO, 63110, USA.
Department of Pharmacy, Barnes-Jewish Hospital, 216 S. Kingshighway Boulevard, St. Louis, MO, 63110, USA.
Neurocrit Care. 2017 Aug;27(1):96-102. doi: 10.1007/s12028-016-0373-4.
Venous thromboembolism (VTE) prophylaxis in underweight patients with neurologic injury remains unaddressed by guidelines and primary literature. This study aimed to describe VTE prophylaxis strategies employed in this population and compare the impact of underweight and non-obese patients on thrombotic and bleeding events.
A retrospective review of adults admitted with a diagnosis of neurologic injury to a neurology/neurosurgery intensive care unit (ICU) over 6 years. Patients admitted ≥72 h with an order for VTE prophylaxis during admission, and a body mass index (BMI) <30 kg/m were included. Patients were stratified to underweight (BMI ≤18.5 kg/m or weight ≤50.0 kg) or non-obese (BMI 18.6-29.9 kg/m) groups and matched, 2:1, on age, diagnosis, and disease severity.
The most common regimen in the underweight (n = 107) and non-obese (n = 214) group was unfractionated heparin (UFH) 5000 units subcutaneously Q12 h (69.1 vs. 83.6%; p = 0.003). Only underweight patients received UFH 2500 units subcutaneously Q12 h (17.8 vs. 0.0%; p < 0.0001). The proportion of overall bleeding and thrombotic events while receiving VTE prophylaxis was not significantly different. The proportion of underweight patients developing intracranial hematoma expansion while receiving prophylaxis versus non-obese patients (45.5 vs. 8.3%; p = 0.017) was significant. Patients receiving >150 units/kg/day of UFH displayed a trend toward increased risk of bleeding (9.7 vs. 4.2%; p = 0.064).
Current practice does not reflect dose reductions for neurologically injured, underweight patients. Caution should be considered when using increased doses of UFH in neurologically injured patients that are underweight and/or may be exposed to >150 units/kg/day of UFH. Continued assessment of VTE prophylaxis is needed to confirm these findings.
神经损伤的体重过轻患者的静脉血栓栓塞症(VTE)预防问题仍未得到指南和主要文献的关注。本研究旨在描述该人群所采用的VTE预防策略,并比较体重过轻和非肥胖患者对血栓形成和出血事件的影响。
对6年间入住神经内科/神经外科重症监护病房(ICU)且诊断为神经损伤的成人患者进行回顾性研究。纳入入院≥72小时且入院期间有VTE预防医嘱、体重指数(BMI)<30kg/m²的患者。患者按体重过轻(BMI≤18.5kg/m²或体重≤50.0kg)或非肥胖(BMI 18.6 - 29.9kg/m²)分层,并按年龄、诊断和疾病严重程度以2:1的比例进行匹配。
体重过轻组(n = 107)和非肥胖组(n = 214)最常用的方案是皮下注射普通肝素(UFH)5000单位,每12小时一次(69.1%对83.6%;p = 0.003)。只有体重过轻的患者接受皮下注射UFH 2500单位,每12小时一次(17.8%对0.0%;p < 0.0001)。接受VTE预防期间总体出血和血栓形成事件的比例无显著差异。体重过轻的患者在接受预防期间发生颅内血肿扩大的比例与非肥胖患者相比(45.5%对8.3%;p = 0.017)有显著差异。接受>150单位/千克/天UFH的患者有出血风险增加的趋势(9.7%对4.2%;p = 0.064)。
目前的做法未体现出对神经损伤的体重过轻患者进行剂量调整。对于体重过轻且/或可能接受>150单位/千克/天UFH的神经损伤患者,使用增加剂量的UFH时应谨慎。需要持续评估VTE预防措施以证实这些发现。